Fate Therapeutics to Present FT839 Data at AACR Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy FATE?
Fate Therapeutics announced that preclinical data from the Company's next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research Annual Meeting, being held in San Diego, CA on April 17-22, 2026. The Company has been selected to participate in a poster presentation featuring preclinical data from FT839, its next generation, 13-point edited, off-the-shelf CAR T-cell product candidate for the broad treatment of hematological malignancies and autoimmune diseases. In addition, FT839 incorporates Sword and Shield technology to evade and eliminate host allogeneic immune responses, promote functional persistence, and thereby eliminate the need for conditioning chemotherapy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FATE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FATE
Wall Street analysts forecast FATE stock price to rise
9 Analyst Rating
5 Buy
4 Hold
0 Sell
Moderate Buy
Current: 1.390
Low
2.00
Averages
4.64
High
8.00
Current: 1.390
Low
2.00
Averages
4.64
High
8.00
About FATE
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
See More
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
See More
Avaí Bio Initiates Production of α-Klotho Cell Bank
- Production Milestone: Avaí Bio, in collaboration with Austrianova, has initiated the production of a Master Cell Bank for the α-Klotho protein, marking a significant transition of its anti-aging program from research to manufacturing, which is expected to enhance the market potential for anti-aging therapies.
- Market Outlook: The global cell and gene therapy market is projected to surge from $10.4 billion to over $45 billion, with Avaí Bio's dual-program strategy targeting major diseases like Alzheimer's and diabetes, leveraging this growth trend effectively.
- Technological Edge: Utilizing the Cell-in-a-Box® technology backed by over 50 peer-reviewed studies, Avaí Bio ensures the efficacy of its products in anti-aging and diabetes treatments, thereby enhancing its competitive position in the biotechnology sector.
- Health Implications: Research links α-Klotho to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, and Avaí Bio's products aim to address the therapeutic gap created by the natural decline of α-Klotho levels after age 40, meeting the rising market demand.
See More
Avaí Bio Advances Cell Therapy Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, driven by clinical breakthroughs and manufacturing milestones, indicating strong growth potential in regenerative medicine.
- CAR T-Cell Therapy Growth: The market value of CAR T-cell therapy is nearly $7 billion this year, with an 18% compound annual growth rate, suggesting that off-the-shelf platforms are eliminating logistical barriers to patient access, further driving market expansion.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, which will provide critical material for scalable cell therapy production, ensuring product consistency and reducing risks.
- Anti-Aging Treatment Prospects: By establishing a high-quality MCB, the collaboration between Avaí Bio and Austrianova will support the development of cell-based therapies targeting aging and related diseases, further advancing the clinical application of α-Klotho to meet growing market demand.
See More
Avaí Bio Advances α-Klotho Cell Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, with CAR T-cell therapy valued at nearly $7 billion this year and an 18% compound annual growth rate, indicating robust growth in the regenerative medicine sector.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has successfully initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, ensuring product consistency and safety, thereby laying the groundwork for anti-aging therapies.
- Significant Technical Advantage: The establishment of the MCB under Good Manufacturing Practices (GMP) not only reduces risks of contamination and genetic instability but also supports sustainable production, reinforcing the company's long-term strategy in the anti-aging sector.
- Successful Strategic Pivot: Following its rebranding, Avaí Bio has focused on biotechnology, leveraging strategic partnerships with Austrianova to advance both the α-Klotho anti-aging program and the Insulinova diabetes program, showcasing its innovative capabilities in cell therapy.
See More
Fate Therapeutics Reports Q4 2025 Revenue and Financial Position
- Q4 Revenue: Fate Therapeutics reported $1.4 million in revenue for Q4 2025, indicating a decline compared to the previous year, yet demonstrating the company's ongoing operational capability in the biopharmaceutical sector.
- Cash and Investment Position: As of December 31, 2025, the company held $205.1 million in cash, cash equivalents, and investments, providing a robust financial foundation for future R&D and market expansion efforts.
- Financial Stability: The company has maintained a solid cash flow position in the current economic environment, ensuring its competitiveness in the biotechnology industry and laying the groundwork for potential collaborations and acquisition opportunities.
- Market Outlook: Despite facing challenges, Fate Therapeutics remains committed to advancing its innovative therapies, with expectations to enhance revenue and shareholder value through new product launches and market expansion in the future.
See More
Avaí Bio Initiates α-Klotho Cell Production Phase
- Market Growth Potential: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating strong growth momentum that drives strategic positioning for companies like Avaí Bio.
- Regulatory Flexibility Enhancement: The FDA's easing of manufacturing requirements for cell and gene therapies accelerates the approval timeline for life-saving products, creating a historic shift that provides companies with scalable bioproduction infrastructure and enhances market competitiveness.
- Cell Bank Development: Avaí Bio, in partnership with Austrianova, has begun manufacturing a Master Cell Bank (MCB) for α-Klotho protein, establishing a stable production foundation that ensures product quality and consistency for future cell therapies.
- Clinical Trial Outlook: The production of α-Klotho cells will directly support Austrianova's Cell-in-a-Box® platform, aiming to provide patients with durable anti-aging treatments, marking a significant advancement for the company in addressing aging-related diseases.
See More
Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
See More
Avaí Bio Initiates Production of α-Klotho Cell Bank
- Production Milestone: Avaí Bio, in collaboration with Austrianova, has initiated the production of a Master Cell Bank for the α-Klotho protein, marking a significant transition of its anti-aging program from research to manufacturing, which is expected to enhance the market potential for anti-aging therapies.
- Market Outlook: The global cell and gene therapy market is projected to surge from $10.4 billion to over $45 billion, with Avaí Bio's dual-program strategy targeting major diseases like Alzheimer's and diabetes, leveraging this growth trend effectively.
- Technological Edge: Utilizing the Cell-in-a-Box® technology backed by over 50 peer-reviewed studies, Avaí Bio ensures the efficacy of its products in anti-aging and diabetes treatments, thereby enhancing its competitive position in the biotechnology sector.
- Health Implications: Research links α-Klotho to reduced risks of Alzheimer's, cardiovascular diseases, and certain cancers, and Avaí Bio's products aim to address the therapeutic gap created by the natural decline of α-Klotho levels after age 40, meeting the rising market demand.
See More
Avaí Bio Advances Cell Therapy Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, driven by clinical breakthroughs and manufacturing milestones, indicating strong growth potential in regenerative medicine.
- CAR T-Cell Therapy Growth: The market value of CAR T-cell therapy is nearly $7 billion this year, with an 18% compound annual growth rate, suggesting that off-the-shelf platforms are eliminating logistical barriers to patient access, further driving market expansion.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, which will provide critical material for scalable cell therapy production, ensuring product consistency and reducing risks.
- Anti-Aging Treatment Prospects: By establishing a high-quality MCB, the collaboration between Avaí Bio and Austrianova will support the development of cell-based therapies targeting aging and related diseases, further advancing the clinical application of α-Klotho to meet growing market demand.
See More
Avaí Bio Advances α-Klotho Cell Production Milestone
- Market Potential: The global cell therapy market is projected to exceed $8.2 billion by 2026, with CAR T-cell therapy valued at nearly $7 billion this year and an 18% compound annual growth rate, indicating robust growth in the regenerative medicine sector.
- Production Milestone Achieved: Avaí Bio and Austrianova's joint venture Klothonova has successfully initiated the production of a Master Cell Bank (MCB) for α-Klotho protein, ensuring product consistency and safety, thereby laying the groundwork for anti-aging therapies.
- Significant Technical Advantage: The establishment of the MCB under Good Manufacturing Practices (GMP) not only reduces risks of contamination and genetic instability but also supports sustainable production, reinforcing the company's long-term strategy in the anti-aging sector.
- Successful Strategic Pivot: Following its rebranding, Avaí Bio has focused on biotechnology, leveraging strategic partnerships with Austrianova to advance both the α-Klotho anti-aging program and the Insulinova diabetes program, showcasing its innovative capabilities in cell therapy.
See More
Fate Therapeutics Reports Q4 2025 Revenue and Financial Position
- Q4 Revenue: Fate Therapeutics reported $1.4 million in revenue for Q4 2025, indicating a decline compared to the previous year, yet demonstrating the company's ongoing operational capability in the biopharmaceutical sector.
- Cash and Investment Position: As of December 31, 2025, the company held $205.1 million in cash, cash equivalents, and investments, providing a robust financial foundation for future R&D and market expansion efforts.
- Financial Stability: The company has maintained a solid cash flow position in the current economic environment, ensuring its competitiveness in the biotechnology industry and laying the groundwork for potential collaborations and acquisition opportunities.
- Market Outlook: Despite facing challenges, Fate Therapeutics remains committed to advancing its innovative therapies, with expectations to enhance revenue and shareholder value through new product launches and market expansion in the future.
See More
